JP6088657B2 - ＤａｇＡ酵素反応で調剤した抗肥満及び抗糖尿効能を有する寒天由来のネオアガロオリゴ糖複合組成物 - Google Patents
ＤａｇＡ酵素反応で調剤した抗肥満及び抗糖尿効能を有する寒天由来のネオアガロオリゴ糖複合組成物 Download PDFInfo
- Publication number
- JP6088657B2 JP6088657B2 JP2015541697A JP2015541697A JP6088657B2 JP 6088657 B2 JP6088657 B2 JP 6088657B2 JP 2015541697 A JP2015541697 A JP 2015541697A JP 2015541697 A JP2015541697 A JP 2015541697A JP 6088657 B2 JP6088657 B2 JP 6088657B2
- Authority
- JP
- Japan
- Prior art keywords
- obesity
- diabetes
- agar
- daga
- reaction product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000006911 enzymatic reaction Methods 0.000 title claims description 42
- 229920001817 Agar Polymers 0.000 title claims description 37
- 239000000203 mixture Substances 0.000 title claims description 35
- 239000008272 agar Substances 0.000 title claims description 34
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims description 33
- 241000534414 Anotopterus nikparini Species 0.000 title claims description 33
- 229920001542 oligosaccharide Polymers 0.000 title claims description 18
- 230000003178 anti-diabetic effect Effects 0.000 title description 9
- 230000003579 anti-obesity Effects 0.000 title description 8
- 239000002131 composite material Substances 0.000 title 1
- 239000007795 chemical reaction product Substances 0.000 claims description 41
- 206010012601 diabetes mellitus Diseases 0.000 claims description 32
- 208000008589 Obesity Diseases 0.000 claims description 29
- 235000020824 obesity Nutrition 0.000 claims description 29
- 229920000936 Agarose Polymers 0.000 claims description 26
- XASQSRDYYCWSME-NWCCWNDLSA-N (2S,3R,4S,5R,6R)-4-[[(1S,3S,4S,5S,8R)-8-[(2S,3R,4S,5S,6R)-4-[[(1S,3S,4S,5R,8R)-4,8-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O[C@@H]2O[C@H]3CO[C@H]([C@@H]3O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O[C@@H]4O[C@H]5CO[C@H]([C@@H]5O)[C@@H]4O)[C@H]3O)[C@@H]2O)[C@@H]1O XASQSRDYYCWSME-NWCCWNDLSA-N 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 10
- 235000013376 functional food Nutrition 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 108700038674 Streptomyces coelicolor dagA Proteins 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 235000010419 agar Nutrition 0.000 description 27
- 230000000694 effects Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 235000009200 high fat diet Nutrition 0.000 description 17
- JWMBOBQNPBCYER-UHFFFAOYSA-N 4-[(4,8-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl)oxy]-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound OC1C(CO)OC(O)C(O)C1OC1C(O)C(C2O)OCC2O1 JWMBOBQNPBCYER-UHFFFAOYSA-N 0.000 description 16
- 235000005911 diet Nutrition 0.000 description 15
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 230000037213 diet Effects 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 206010022489 Insulin Resistance Diseases 0.000 description 11
- 241000187747 Streptomyces Species 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 241000186361 Actinobacteria <class> Species 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 101150005799 dagA gene Proteins 0.000 description 9
- 210000005228 liver tissue Anatomy 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 108010045649 agarase Proteins 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102000011690 Adiponectin Human genes 0.000 description 6
- 108010076365 Adiponectin Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 102000004139 alpha-Amylases Human genes 0.000 description 6
- 108090000637 alpha-Amylases Proteins 0.000 description 6
- 229940024171 alpha-amylase Drugs 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 4
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229960002632 acarbose Drugs 0.000 description 4
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 4
- 108010028144 alpha-Glucosidases Proteins 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000007863 steatosis Effects 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 230000002381 testicular Effects 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- JPLATTLXZFUKRQ-UHFFFAOYSA-N Agarobiose Natural products OCC1OC(OC2C(O)COC2C(O)C=O)C(O)C(O)C1O JPLATTLXZFUKRQ-UHFFFAOYSA-N 0.000 description 3
- 101710110830 Beta-agarase Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 235000015429 Mirabilis expansa Nutrition 0.000 description 3
- 244000294411 Mirabilis expansa Species 0.000 description 3
- 241000187398 Streptomyces lividans Species 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000000105 evaporative light scattering detection Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000002414 glycolytic effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 235000013536 miso Nutrition 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241001446247 uncultured actinomycete Species 0.000 description 3
- WZYRMLAWNVOIEX-MOJAZDJTSA-N (2s)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyacetaldehyde Chemical compound O=C[C@@H](O)[C@@H]1OC[C@H](O)[C@H]1O WZYRMLAWNVOIEX-MOJAZDJTSA-N 0.000 description 2
- WDMUXYQIMRDWRC-UHFFFAOYSA-N 2-hydroxy-3,4-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1O WDMUXYQIMRDWRC-UHFFFAOYSA-N 0.000 description 2
- DCQFFOLNJVGHLW-UHFFFAOYSA-N 4'-Me ether-Punctatin+ Natural products O1C(O)C(O)C2OCC1C2O DCQFFOLNJVGHLW-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 101100055031 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) dagA gene Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- WZYRMLAWNVOIEX-UHFFFAOYSA-N cinnamtannin B-2 Natural products O=CC(O)C1OCC(O)C1O WZYRMLAWNVOIEX-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000350481 Pterogyne nitens Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001446311 Streptomyces coelicolor A3(2) Species 0.000 description 1
- 241000828254 Streptomyces lividans TK24 Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 235000021105 fermented cheese Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000021264 seasoned food Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 101150115529 tagA gene Proteins 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/729—Agar; Agarose; Agaropectin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120128087 | 2012-11-13 | ||
| KR10-2012-0128087 | 2012-11-13 | ||
| KR10-2013-0137079 | 2013-11-12 | ||
| KR1020130137079A KR101632262B1 (ko) | 2012-11-13 | 2013-11-12 | DagA 효소반응으로 조제한 항비만 및 항당뇨 효능을 갖는 한천 유래 네오아가로올리고당 복합 조성물 |
| PCT/KR2013/010277 WO2014077575A1 (ko) | 2012-11-13 | 2013-11-13 | 덱에이 효소반응으로 조제한 항비만 및 항당뇨 효능을 갖는 한천 유래 네오아가로올리고당 복합 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016505521A JP2016505521A (ja) | 2016-02-25 |
| JP6088657B2 true JP6088657B2 (ja) | 2017-03-01 |
Family
ID=50890329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015541697A Active JP6088657B2 (ja) | 2012-11-13 | 2013-11-13 | ＤａｇＡ酵素反応で調剤した抗肥満及び抗糖尿効能を有する寒天由来のネオアガロオリゴ糖複合組成物 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP6088657B2 (ko) |
| KR (1) | KR101632262B1 (ko) |
| CN (1) | CN104780943B (ko) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101675359B1 (ko) * | 2014-12-30 | 2016-11-14 | 건국대학교 글로컬산학협력단 | 네오아가로올리고당을 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 조성물 |
| US10933086B2 (en) | 2016-10-27 | 2021-03-02 | Dynebio Inc. | Composition for preventing, alleviating, or treating arthritis or osteoporosis, containing neoagarooligosaccharide |
| KR102032799B1 (ko) | 2017-11-16 | 2019-10-17 | 고려대학교 산학협력단 | 해조류 유래 아가로트리오스의 제조방법 및 프리바이오틱로서의 용도 |
| KR102214973B1 (ko) * | 2019-06-04 | 2021-02-10 | 다인바이오 주식회사 | 네오아가로올리고당 혼합물 원료용 한천의 제조방법 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62210965A (ja) * | 1986-03-13 | 1987-09-17 | Shokuhin Sangyo Baioriakutaa Syst Gijutsu Kenkyu Kumiai | 低カロリ−飲食品およびその製造方法 |
| WO2000043018A1 (fr) * | 1999-01-20 | 2000-07-27 | Takara Shuzo Co., Ltd. | Compositions medicamenteuses |
| TWI247585B (en) * | 1999-05-14 | 2006-01-21 | Takara Bio Inc | Agarobiose-containing composition |
| ATE392477T1 (de) * | 2001-02-27 | 2008-05-15 | Takara Bio Inc | Agarase und gen dafür |
| CN1189472C (zh) * | 2002-06-06 | 2005-02-16 | 严小军 | 一种低聚寡糖的应用 |
| KR101233766B1 (ko) | 2010-02-11 | 2013-02-15 | 명지대학교 산학협력단 | 베타―아가레즈의 생산을 위한 재조합 발현 벡터 |
| KR101190078B1 (ko) * | 2011-11-29 | 2012-10-11 | 명지대학교 산학협력단 | 베타-아가레즈 재조합 발현 벡터, 형질전환 균주 및 베타-아가레즈 생산 방법 |
-
2013
- 2013-11-12 KR KR1020130137079A patent/KR101632262B1/ko active IP Right Grant
- 2013-11-13 JP JP2015541697A patent/JP6088657B2/ja active Active
- 2013-11-13 CN CN201380059074.6A patent/CN104780943B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016505521A (ja) | 2016-02-25 |
| CN104780943A (zh) | 2015-07-15 |
| CN104780943B (zh) | 2017-06-23 |
| KR101632262B9 (ko) | 2022-08-16 |
| KR101632262B1 (ko) | 2016-06-21 |
| KR20140061272A (ko) | 2014-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7064435B2 (ja) | α－１，２－分岐鎖を有するグルカンを生成することができるポリペプチドおよびその使用 | |
| JP6005558B2 (ja) | リポ多糖、リポ多糖製造方法及びリポ多糖配合物 | |
| JP6088657B2 (ja) | ＤａｇＡ酵素反応で調剤した抗肥満及び抗糖尿効能を有する寒天由来のネオアガロオリゴ糖複合組成物 | |
| JP6815525B2 (ja) | ネオアガロオリゴ糖を含む関節炎または骨粗しょう症の予防、改善または治療用組成物 | |
| US10548916B2 (en) | Composition comprising neoagarooligosaccharide as active ingredient, for prevention or treatment of sepsis or septic shock | |
| CN1324234A (zh) | 果糖胺氧化酶,拮抗剂和抑制剂 | |
| JP5992902B2 (ja) | 改変型α−グルコシダーゼ及びその用途 | |
| TW201717778A (zh) | 解澱粉芽孢桿菌、穀物醱酵物、其製備方法及其用途、食品組成物、血栓分解用組成物、消化改善用組成物、腸炎、腸膜弱化或腸損傷的預防、改善或治療用組成物及抗氧化用組成物 | |
| US20220118061A1 (en) | Microbial Lysozyme for use in the Treatment of Irritable Bowel Syndrome or Inflammatory Bowel Disease | |
| JP6096179B2 (ja) | ラクターゼ活性を有するタンパク質、該タンパク質をコードする遺伝子、該遺伝子を含有する組み換えベクター、形質転換体、及びその製造方法並びに用途 | |
| US11236315B2 (en) | Thermophile peptidoglycan hydrolase fusion proteins and uses thereof | |
| KR20160020457A (ko) | 네오아가로올리고당을 포함하는 면역 증강용 또는 항암용 조성물 | |
| WO2014077575A1 (ko) | 덱에이 효소반응으로 조제한 항비만 및 항당뇨 효능을 갖는 한천 유래 네오아가로올리고당 복합 조성물 | |
| JP2008222701A (ja) | 肥満予防及び治療用発酵物、糖尿病予防用発酵物、肥満予防及び治療用発酵食品および糖尿病予防用食品 | |
| KR102032799B1 (ko) | 해조류 유래 아가로트리오스의 제조방법 및 프리바이오틱로서의 용도 | |
| CN113748120B (zh) | 肽、组合物及饥饿素分泌促进剂 | |
| KR20180046392A (ko) | 네오아가로올리고당을 포함하는 관절염 예방, 개선 또는 치료용 조성물 | |
| WO2022080245A1 (ja) | 乳酸菌の菌体外多糖の免疫賦活活性の向上作用を有するタンパク質、並びに、それを用いた発酵乳及びその製造方法 | |
| KR101813703B1 (ko) | 모노아실글리세롤 리파아제의 대량생산 방법 | |
| KR102132743B1 (ko) | 해조류 유래 아가로트리오스의 제조방법 및 프리바이오틱로서의 용도 | |
| WO2022234671A1 (ja) | Ｄ－アルロースの機能性を持つ砂糖に近い味質の甘味料の大量生産方法 | |
| KR101923062B1 (ko) | 네오아가로올리고당을 포함하는 골다공증 예방, 개선 또는 치료용 조성물 | |
| EP2975113A1 (en) | Variant of cellulase-producing fungus, cellulase manufacturing method, and cello-oligosaccharide manufacturing method | |
| Suzuki et al. | Construction of “toxin complex” in a mutant serotype C strain of Clostridium botulinum harboring a defective neurotoxin gene | |
| EP3269731B1 (en) | Molecular design of recombinant protein drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160509 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160809 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160906 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161202 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170113 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170203 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6088657 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |